Literature DB >> 27187749

Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection.

K V Shmagel1,2, E V Saidakova1,2, N G Shmagel2,3, L B Korolevskaya1,2, V A Chereshnev1,2,4, J Robinson5, J-C Grivel6, D C Douek7, L Margolis6, D D Anthony5, M M Lederman5.   

Abstract

OBJECTIVES: Chronic hepatitis C virus (HCV) and HIV viral infections are characterized by systemic inflammation. Yet the relative levels, drivers and correlates of inflammation in these settings are not well defined.
METHODS: Seventy-nine HIV-infected patients who had been receiving antiretroviral therapy (ART) for more than 2 years and who had suppressed plasma HIV levels (< 50 HIV-1 RNA copies/mL) were included in the study. Two patient groups, HCV-positive/HIV-positive and HCV-negative/HIV-positive, and a control group comprised of healthy volunteers (n = 20) were examined. Markers of systemic inflammation [interleukin (IL)-6, interferon gamma-induced protein (IP)-10, soluble tumour necrosis factor receptor-I (sTNF-RI) and sTNF-RII], monocyte/macrophage activation [soluble CD163 (sCD163), soluble CD14 and neopterin], intestinal epithelial barrier loss [intestinal fatty acid binding protein (I-FABP) and lipopolysaccharide (LPS)] and coagulation (d-dimers) were analysed. CD4 naïve T cells and CD4 recent thymic emigrants (RTEs) were enumerated.
RESULTS: Plasma levels of IP-10, neopterin and sCD163 were higher in HCV/HIV coinfection than in HIV monoinfection and were positively correlated with indices of hepatic damage [aspartate aminotransferase (AST), alanine aminotransferase (ALT) and the AST to platelet ratio index (APRI)]. Levels of I-FABP were comparably increased in HIV monoinfection and HIV/HCV coinfection but LPS concentrations were highest in HCV/HIV coinfection, suggesting impaired hepatic clearance of LPS. Plasma HCV levels were not related to any inflammatory indices except sCD163. In coinfected subjects, a previously recognized relationship of CD4 naïve T-cell and RTE counts to hepatocellular injury was defined more mechanistically by an inverse relationship to sCD163.
CONCLUSIONS: Hepatocellular injury in HCV/HIV coinfection is linked to elevated levels of certain inflammatory cytokines and an apparent failure to clear systemically translocated microbial products. A related decrease in CD4 naïve T cells and RTEs also merits further exploration.
© 2016 British HIV Association.

Entities:  

Keywords:  CD31; HIV infections; antigens; hepatitis C; highly active antiretroviral therapy; inflammation mediators

Mesh:

Substances:

Year:  2016        PMID: 27187749      PMCID: PMC4987156          DOI: 10.1111/hiv.12357

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.094


  40 in total

Review 1.  Role of inflammation in HIV-1 disease progression and prognosis.

Authors:  Hayley Ipp; Annalise E Zemlin; Rajiv T Erasmus; Richard H Glashoff
Journal:  Crit Rev Clin Lab Sci       Date:  2014-01-30       Impact factor: 6.250

2.  Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.

Authors:  P L Shields; C M Morland; M Salmon; S Qin; S G Hubscher; D H Adams
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

3.  Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients.

Authors:  Marina Núñez; Vincent Soriano; Mariola López; Celia Ballesteros; Almudena Cascajero; Juan González-Lahoz; Jose Miguel Benito
Journal:  Clin Infect Dis       Date:  2006-09-27       Impact factor: 9.079

4.  Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection.

Authors:  Nicole L Yonkers; Scott Sieg; Benigno Rodriguez; Donald D Anthony
Journal:  J Infect Dis       Date:  2011-01-10       Impact factor: 5.226

5.  Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.

Authors:  E S Andersen; S Rødgaard-Hansen; B Moessner; P B Christensen; H J Møller; Nina Weis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-10       Impact factor: 3.267

6.  Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus.

Authors:  Audrey L French; Charlesnika T Evans; Denis M Agniel; Mardge H Cohen; Marion Peters; Alan L Landay; Seema N Desai
Journal:  J Infect Dis       Date:  2013-05-17       Impact factor: 5.226

7.  Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.

Authors:  Marija Zeremski; Lydia M Petrovic; Luis Chiriboga; Queenie B Brown; Herman T Yee; Milan Kinkhabwala; Ira M Jacobson; Rositsa Dimova; Marianthi Markatou; Andrew H Talal
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

8.  Towards hepatitis C eradication from the HIV-infected population.

Authors:  Pablo Barreiro; Jose Vicente Fernandez-Montero; Carmen de Mendoza; Pablo Labarga; Vincent Soriano
Journal:  Antiviral Res       Date:  2014-02-15       Impact factor: 5.970

9.  Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins.

Authors:  A Apolinario; P L Majano; R Lorente; O Núñez; G Clemente; C García-Monzón
Journal:  J Viral Hepat       Date:  2005-01       Impact factor: 3.728

10.  Complementary role of HCV and HIV in T-cell activation and exhaustion in HIV/HCV coinfection.

Authors:  Thijs Feuth; Joop E Arends; Justin H Fransen; Nening M Nanlohy; Karel J van Erpecum; Peter D Siersema; Andy I M Hoepelman; Debbie van Baarle
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

View more
  26 in total

1.  The Activation State of CD4 T Cells Alters Cellular Peptidase Activities, HIV Antigen Processing, and MHC Class I Presentation in a Sequence-Dependent Manner.

Authors:  Julie Boucau; Julien Madouasse; Georgio Kourjian; Christopher S Carlin; Daniel Wambua; Matthew J Berberich; Sylvie Le Gall
Journal:  J Immunol       Date:  2019-04-01       Impact factor: 5.422

Review 2.  What Is a Host? Attributes of Individual Susceptibility.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2018-01-22       Impact factor: 3.441

3.  HCV coinfection of the HIV-infected patients with discordant CD4+ T-cell response to antiretroviral therapy leads to intense systemic inflammation.

Authors:  K V Shmagel; L B Korolevskaya; E V Saidakova; N G Shmagel; V A Chereshnev; L Margolis; D Anthony; M Lederman
Journal:  Dokl Biol Sci       Date:  2018-01-04

4.  Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.

Authors:  Saverio G Parisi; Samantha Andreis; Carlo Mengoli; Nicola Menegotto; Silvia Cavinato; Renzo Scaggiante; Massimo Andreoni; Giorgio Palù; Monica Basso; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2018-03-09       Impact factor: 3.402

Review 5.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

Review 6.  Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era.

Authors:  Eric G Meissner
Journal:  Curr Opin Gastroenterol       Date:  2017-05       Impact factor: 3.287

7.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Authors:  Saverio G Parisi; Samantha Andreis; Monica Basso; Silvia Cavinato; Renzo Scaggiante; Marzia Franzetti; Massimo Andreoni; Giorgio Palù; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2017-09-01       Impact factor: 3.402

8.  Hepatitis C Virus Cure in Human Immunodeficiency Virus Coinfection Dampens Inflammation and Improves Cognition Through Multiple Mechanisms.

Authors:  Bing Sun; Linda Abadjian; Alexander Monto; Heather Freasier; Lynn Pulliam
Journal:  J Infect Dis       Date:  2020-07-06       Impact factor: 5.226

9.  Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.

Authors:  Anna Lidofsky; Jacinta A Holmes; Eoin R Feeney; Annie J Kruger; Shadi Salloum; Hui Zheng; Isabel S Seguin; Akif Altinbas; Ricard Masia; Kathleen E Corey; Jenna L Gustafson; Esperance A Schaefer; Peter W Hunt; Steven Deeks; Ma Somsouk; Kara W Chew; Raymond T Chung; Nadia Alatrakchi
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

10.  HIV Infection, HCV Coinfection, and Alcohol Use: Associations with Microbial Translocation and Immune Activation.

Authors:  Mollie A Monnig; Ronald Cohen; Bharat Ramratnam; Mikayla McAdams; Karen Tashima; Peter M Monti
Journal:  Alcohol Clin Exp Res       Date:  2019-04-29       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.